dalteparin sodium

Phase 3Small molecule

Pfizer

dalteparin sodium is one of 27 small molecule programs targeting Prophylaxis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProphylaxisRecruiting

ProphylaxisPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in Prophylaxis

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Approved

13 2

Eliquis

Bristol-Myers Squibb

Approved

2 3

Bayer Aspirin

Bayer

Approved

2 4

Cymbalta

Jazz Pharmaceuticals

Approved

1 5

Coreg

Akero Therapeutics

Approved

4 6

Xarelto

WWim Janssens

Approved

4 7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 8

Cabenuva

GSK

Phase 3

2 9

Lovenox

Sanofi

Phase 3

1 10

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Clinical

Trials by Indication[1]

Prophylaxis2 trials

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

Completed·OOttawa Hospital Research Institute·Phase 3·NCT01274637·62 enrolled

Venous Thromboembolism2 trials

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

Completed·—·N/A·NCT01050153·50 enrolled

Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study

Terminated· Pfizer logo

Pfizer·Phase 4·NCT00655122·8 enrolled

Thrombosis1 trial

Treatment of Upper Extremity Deep-Vein Thrombosis

Completed·UUniversity of Oklahoma·Phase 4·NCT00245856·67 enrolled

Thrombophlebitis1 trial

Management of Superficial Thrombophlebitis

Completed·UUniversity of Oklahoma·Phase 4·NCT00264381·72 enrolled

Thrombophilia1 trial

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

Completed·OOttawa Hospital Research Institute·Phase 3·NCT00967382·292 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for dalteparin sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dalteparin sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dalteparin sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

dalteparin sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prophylaxis2 trials

Venous Thromboembolism2 trials

Thrombosis1 trial

Thrombophlebitis1 trial

Thrombophilia1 trial

References

Drug Info

Quick Facts

Related News